Scottish Enterprise

Mask Logic is a manufacturer of personalized protective gear specializing in respirators designed for safety and comfort. The company focuses on creating masks that offer respiratory protection, aiming to enhance health and safety in various workplace environments. By providing effective barriers against airborne health hazards, Mask Logic enables users to work with reduced risk of exposure to harmful particles, thus prioritizing the well-being of individuals in diverse settings.

Cytomos Limited is a biotechnology company based in Edinburgh, United Kingdom, that specializes in developing advanced cell sorting devices for laboratory research and clinical diagnostics. Founded in 2011, the company utilizes its patented Dielectric Spectroscopy (CDS) technology to enable label-free cell analysis, providing detailed insights at single-cell resolution. This technology supports various applications in biopharma and cell therapy by facilitating automated, quantitative assessments of samples and enhancing phenotypic drug discovery. Cytomos’ system is designed to scale across all upstream production stages, leveraging machine learning algorithms to analyze extensive data from individual cells, thus improving the efficiency of cell-based diagnostics and enabling researchers to optimize therapeutic dosing.

Neuranics is a company focused on developing advanced magnetic sensors integrated with semiconductor technology for applications in health, fitness, and the metaverse. Their proprietary technology is designed to detect minute magnetic impulses produced by the body's organs, utilizing scalable spintronics sensors. This innovative approach aims to address the limitations of current health monitoring devices and enhance human-machine interfaces. By leveraging magnetic sensing, Neuranics seeks to improve the interaction with the central, peripheral, and autonomic nervous systems, as well as muscles, thereby offering significant advancements for healthcare companies in creating next-generation wearable and implantable devices.

Metacarpal specializes in the development of innovative bionic prosthetic hands designed to enhance the quality of life for individuals with limb differences. Their pioneering technology features fully mechanical prostheses capable of variable grips, allowing users to effortlessly switch between different hand positions for various tasks. This adaptability ensures a secure grip on objects of varying shapes and sizes, complemented by a grip lock feature for added stability. By integrating intuitive control mechanisms reminiscent of body-powered devices, Metacarpal aims to provide users with a natural and responsive experience. In addition to serving individuals in developed regions, the company is committed to supplying prosthetics to underprivileged communities in the developing world, addressing a critical need for accessible assistive technology.

Chromacity Ltd. is a company based in Edinburgh, United Kingdom, that specializes in the development, manufacture, and distribution of wavelength tunable femtosecond lasers for various applications in life sciences and spectroscopy. The company's product lineup includes several advanced laser systems, such as the Spark 1030-nm and Spark-HP 1040-nm femtosecond lasers, which are designed for high performance and versatility. Additionally, Chromacity offers femtosecond optical parametric oscillators (OPOs), such as the Spark-OPO and Spark-ultra, which produce tunable femtosecond pulses across a broad range of wavelengths. The technology is built on robust, patent-pending fiber-laser innovations, providing reliable and user-friendly operation through an embedded web server. Chromacity also collaborates with systems manufacturers to supply custom OEM femtosecond and picosecond lasers tailored to specific engineering and materials processing needs. Founded in 2013 as a spin-out from Heriot-Watt University, the company leverages over 40 years of expertise in ultrafast lasers and serves clients in North America, the United Kingdom, the Middle East, and beyond.

Mirna is a veterinary diagnostics company that specializes in the development of veterinary disease testing technology.

Nami Surgical specializes in developing and providing advanced robotic surgery technology. Their core offering is ultrasonic surgical tools designed to enhance the current robotic-assisted surgery market. By simplifying and making procedures safer, they expand the use of robots in surgeries requiring ultrasonic devices, thereby improving clinical outcomes and patient care. Their solutions provide surgeons with intuitive, high-performance, and maneuverable instruments for complex surgical tasks.

Nebu-Flow is a manufacturer focused on developing advanced inhaled drug delivery systems for patients with respiratory disorders. The company specializes in innovative technology that controls droplet size to enhance deep lung deposition, facilitating effective drug delivery through inhalation. This technology not only targets existing formulations but also accommodates emerging therapeutics, including biologics, nanomedicines, and vaccines. By enabling injection-free systemic drug delivery, Nebu-Flow aims to improve treatment options for various respiratory, cardiovascular, and central nervous system conditions. The company is also dedicated to minimizing its environmental impact while ensuring its nebulizers remain user-friendly and high-performing.

Medical Device Manufacturing Centre provides medical device developers and manufacturers with the advice, technical expertise, and facilities essential for companies that are seeking to translate medical device concepts into commercial products.

Microplate Dx is a developer of diagnostic technology focused on reducing fatalities from drug-resistant infections. As an award-winning spinout from the University of Strathclyde in Glasgow, the company aims to address the global health challenge of antimicrobial resistance. Microplate Dx's innovative solutions utilize highly sensitive biosensor electrodes, combined with miniaturized hydrogel deposits containing antibiotics specific to the infection being detected. Their medical diagnostic device provides a low-cost and accurate point-of-care alternative, enabling rapid antibiotic prescribing in under one hour. This approach enhances antibiotic stewardship and strives to manage the spread of antimicrobial resistance effectively.

Cytomos Limited is a biotechnology company based in Edinburgh, United Kingdom, that specializes in developing advanced cell sorting devices for laboratory research and clinical diagnostics. Founded in 2011, the company utilizes its patented Dielectric Spectroscopy (CDS) technology to enable label-free cell analysis, providing detailed insights at single-cell resolution. This technology supports various applications in biopharma and cell therapy by facilitating automated, quantitative assessments of samples and enhancing phenotypic drug discovery. Cytomos’ system is designed to scale across all upstream production stages, leveraging machine learning algorithms to analyze extensive data from individual cells, thus improving the efficiency of cell-based diagnostics and enabling researchers to optimize therapeutic dosing.

Manus Neurodynamica Ltd specializes in manufacturing medical diagnostic technologies aimed at identifying and monitoring neuromotor impairments, particularly focusing on Parkinson's disease. Founded in 2008 and based in North Shields, United Kingdom, the company has developed a triage device that supports early diagnostics for this condition. Its innovative technology integrates analytical software to assess a patient's movement parameters by examining subtle limb and hand motions. This capability allows clinicians to quantify fine motor skills and motion features, enhancing the diagnosis and ongoing monitoring of Parkinson's disease. Manus Neurodynamica's solutions are utilized across various sectors, including academic and pharmaceutical research, as well as non-medical applications, contributing to improved efficiency and reduced costs in specialist neuromotor services.

IbisVision Limited specializes in developing a visual field test software application aimed at the early detection of glaucoma, a leading cause of blindness worldwide. The company's primary product, Ring of Sight (ROS), is a cloud-based solution that enables healthcare professionals to conduct eye tests efficiently. Utilizing patented technology, ROS integrates various eye tests into a single device, offering both Full Threshold and Suprathreshold tests. It is designed for remote and in-practice use, allowing optometrists to deliver high-quality eye care while optimizing their investment. The application operates within a Windows environment and ensures that all patient data is securely stored on encrypted servers to uphold privacy and security. Founded in 2013 and headquartered in Livingston, United Kingdom, IbisVision is committed to advancing eye care through innovative technology.

Merck, established in 1668, is a global science and technology company operating in three main segments: Life Science, Performance Materials, and Healthcare. The Life Science division (44% of 2023 sales) supplies laboratory consumables and services to researchers, while the Healthcare segment (38%) focuses on developing, manufacturing, and selling branded pharmaceuticals, with key therapeutic areas in oncology, multiple sclerosis, and fertility. The Electronics segment (17%) provides specialty materials for various industries, including semiconductors, electronics, and cosmetics. Merck's extensive global presence spans over 100 countries, with significant operations in Europe, Asia, and emerging markets. The company is committed to partnerships, innovation, and improving lives through its products and solutions.

Dxcover is a clinical-stage liquid biopsy company based in Glasgow, founded in 2016 by David S Palmer, Holly Butler, and Matthew Baker. The firm focuses on developing innovative diagnostics for the early detection of various cancers, which is crucial for improving treatment outcomes. Dxcover has pioneered the use of infrared spectroscopy combined with artificial intelligence to analyze circulating pan-omic indicators, allowing for the identification of cancer from a simple blood sample. This approach enables same-day diagnosis and patient stratification, facilitating timely interventions. The company has demonstrated strong clinical data supporting the accurate diagnosis of Stage I and Stage II cancers, underscoring its commitment to enhancing survival rates and quality of life for patients.

Waire Health specializes in the development of wearable vital sign monitoring devices aimed at identifying high-risk patients in hospital wards and at home. By employing advanced artificial intelligence, the company's technology continuously monitors vital signs to detect patterns that may indicate the onset of conditions such as sepsis. This proactive monitoring allows clinicians to receive timely information, facilitating early intervention and improving patient outcomes. By operating autonomously, Waire's solutions help reduce healthcare costs while enhancing the quality of care for patients.

CardioPrecision Ltd, established in 2007 and based in Glasgow, United Kingdom, specializes in the development of innovative medical devices for invasive cardiovascular surgery. The company has created a patented technology that allows medical professionals to conduct minimally invasive procedures with minimal neck access. Its flagship device is a retractor that illuminates different zones of the operative field, facilitating the various steps of cardiothoracic operations through a short incision in the skin crease of the neck. This advancement enables endoscopic vessel harvesting operators to control the monitor's position and perform procedures from a comfortable, upright posture, ultimately enhancing precision during less invasive aortic valve replacement surgeries.

Bioliberty is a medtech start-up focused on creating innovative rehabilitation solutions for individuals with degenerative and traumatic conditions. The company develops robotic gloves that leverage artificial intelligence to facilitate muscle recovery. By utilizing assistive robotics and rehabilitative devices, Bioliberty aims to support patients suffering from various ailments, including stroke, motor neuron disease, multiple sclerosis, rheumatoid arthritis, and osteoarthritis. These devices are designed to assist users in overcoming hand weakness, enabling them to perform daily tasks more effectively and enhance their hand strength, ultimately promoting greater independence and comfort in their own homes.

Cytomos Limited is a biotechnology company based in Edinburgh, United Kingdom, that specializes in developing advanced cell sorting devices for laboratory research and clinical diagnostics. Founded in 2011, the company utilizes its patented Dielectric Spectroscopy (CDS) technology to enable label-free cell analysis, providing detailed insights at single-cell resolution. This technology supports various applications in biopharma and cell therapy by facilitating automated, quantitative assessments of samples and enhancing phenotypic drug discovery. Cytomos’ system is designed to scale across all upstream production stages, leveraging machine learning algorithms to analyze extensive data from individual cells, thus improving the efficiency of cell-based diagnostics and enabling researchers to optimize therapeutic dosing.

Epipole Ltd. is a UK-based company specializing in the design and manufacture of advanced retinal video cameras, known as the EpiCam series. Founded in 2011 and headquartered in Rosyth, the company aims to enhance the early diagnosis and monitoring of retinal diseases, particularly diabetic retinopathy. The EpiCam family includes the EpiCam M, a hand-held digital retinal camera that allows real-time exploration of retinal vasculature; the EpiCam C, which provides an expanded field of view; and the EpiCam V, designed specifically for veterinary use. Additionally, Epipole offers the Model Eye, an optical replica of the human eye for training purposes. Through a network of distributors and online platforms, Epipole aims to revolutionize ophthalmic practice by introducing innovative imaging solutions that improve clinical understanding and patient outcomes.

Chromacity Ltd. is a company based in Edinburgh, United Kingdom, that specializes in the development, manufacture, and distribution of wavelength tunable femtosecond lasers for various applications in life sciences and spectroscopy. The company's product lineup includes several advanced laser systems, such as the Spark 1030-nm and Spark-HP 1040-nm femtosecond lasers, which are designed for high performance and versatility. Additionally, Chromacity offers femtosecond optical parametric oscillators (OPOs), such as the Spark-OPO and Spark-ultra, which produce tunable femtosecond pulses across a broad range of wavelengths. The technology is built on robust, patent-pending fiber-laser innovations, providing reliable and user-friendly operation through an embedded web server. Chromacity also collaborates with systems manufacturers to supply custom OEM femtosecond and picosecond lasers tailored to specific engineering and materials processing needs. Founded in 2013 as a spin-out from Heriot-Watt University, the company leverages over 40 years of expertise in ultrafast lasers and serves clients in North America, the United Kingdom, the Middle East, and beyond.

Dxcover is a clinical-stage liquid biopsy company based in Glasgow, founded in 2016 by David S Palmer, Holly Butler, and Matthew Baker. The firm focuses on developing innovative diagnostics for the early detection of various cancers, which is crucial for improving treatment outcomes. Dxcover has pioneered the use of infrared spectroscopy combined with artificial intelligence to analyze circulating pan-omic indicators, allowing for the identification of cancer from a simple blood sample. This approach enables same-day diagnosis and patient stratification, facilitating timely interventions. The company has demonstrated strong clinical data supporting the accurate diagnosis of Stage I and Stage II cancers, underscoring its commitment to enhancing survival rates and quality of life for patients.

Epipole Ltd. is a UK-based company specializing in the design and manufacture of advanced retinal video cameras, known as the EpiCam series. Founded in 2011 and headquartered in Rosyth, the company aims to enhance the early diagnosis and monitoring of retinal diseases, particularly diabetic retinopathy. The EpiCam family includes the EpiCam M, a hand-held digital retinal camera that allows real-time exploration of retinal vasculature; the EpiCam C, which provides an expanded field of view; and the EpiCam V, designed specifically for veterinary use. Additionally, Epipole offers the Model Eye, an optical replica of the human eye for training purposes. Through a network of distributors and online platforms, Epipole aims to revolutionize ophthalmic practice by introducing innovative imaging solutions that improve clinical understanding and patient outcomes.

Manus Neurodynamica Ltd specializes in manufacturing medical diagnostic technologies aimed at identifying and monitoring neuromotor impairments, particularly focusing on Parkinson's disease. Founded in 2008 and based in North Shields, United Kingdom, the company has developed a triage device that supports early diagnostics for this condition. Its innovative technology integrates analytical software to assess a patient's movement parameters by examining subtle limb and hand motions. This capability allows clinicians to quantify fine motor skills and motion features, enhancing the diagnosis and ongoing monitoring of Parkinson's disease. Manus Neurodynamica's solutions are utilized across various sectors, including academic and pharmaceutical research, as well as non-medical applications, contributing to improved efficiency and reduced costs in specialist neuromotor services.

Adaptix Limited, established in 2009 and headquartered in Oxford, UK, specializes in designing and manufacturing innovative 3D radiology imaging equipment for X-ray applications. The company's core product is a miniaturized, flat panel X-ray source that can be integrated into existing product lines, enabling manufacturers to offer low-dose 3D imaging capabilities at a more affordable price point and with enhanced portability. Adaptix's solutions are used in various medical fields, including bedside chest imaging, extremity imaging, dental imaging, and breast imaging, with the potential to improve diagnostic accuracy for conditions like cardiovascular and pulmonary diseases, lung cancer, and osteoporosis. The company's technology, based on a pixelated array made in a semiconductor foundry, is protected by patents and leverages existing technologies from various industries. Adaptix's products are components intended for integration by X-ray systems manufacturers, who are responsible for product qualification, validation, and regulatory compliance.

M Squared Lasers is a manufacturer of advanced lasers and photonic instruments designed to enhance capabilities, reliability, and usability across various industrial and scientific sectors. With over twenty years of experience, the company specializes in harnessing the power of light to drive innovation and facilitate cross-sector partnerships. Its product offerings cater to diverse industries, including manufacturing, oil and gas, space technology, and healthcare. M Squared's technology plays a significant role in breakthroughs in fields such as dementia research, cancer diagnosis, and whiskey maturation. By providing cutting-edge solutions, M Squared Lasers aims to address complex challenges and accelerate advancements in multiple applications.

Dxcover is a clinical-stage liquid biopsy company based in Glasgow, founded in 2016 by David S Palmer, Holly Butler, and Matthew Baker. The firm focuses on developing innovative diagnostics for the early detection of various cancers, which is crucial for improving treatment outcomes. Dxcover has pioneered the use of infrared spectroscopy combined with artificial intelligence to analyze circulating pan-omic indicators, allowing for the identification of cancer from a simple blood sample. This approach enables same-day diagnosis and patient stratification, facilitating timely interventions. The company has demonstrated strong clinical data supporting the accurate diagnosis of Stage I and Stage II cancers, underscoring its commitment to enhancing survival rates and quality of life for patients.

Adaptix Limited, established in 2009 and headquartered in Oxford, UK, specializes in designing and manufacturing innovative 3D radiology imaging equipment for X-ray applications. The company's core product is a miniaturized, flat panel X-ray source that can be integrated into existing product lines, enabling manufacturers to offer low-dose 3D imaging capabilities at a more affordable price point and with enhanced portability. Adaptix's solutions are used in various medical fields, including bedside chest imaging, extremity imaging, dental imaging, and breast imaging, with the potential to improve diagnostic accuracy for conditions like cardiovascular and pulmonary diseases, lung cancer, and osteoporosis. The company's technology, based on a pixelated array made in a semiconductor foundry, is protected by patents and leverages existing technologies from various industries. Adaptix's products are components intended for integration by X-ray systems manufacturers, who are responsible for product qualification, validation, and regulatory compliance.

Chromacity Ltd. is a company based in Edinburgh, United Kingdom, that specializes in the development, manufacture, and distribution of wavelength tunable femtosecond lasers for various applications in life sciences and spectroscopy. The company's product lineup includes several advanced laser systems, such as the Spark 1030-nm and Spark-HP 1040-nm femtosecond lasers, which are designed for high performance and versatility. Additionally, Chromacity offers femtosecond optical parametric oscillators (OPOs), such as the Spark-OPO and Spark-ultra, which produce tunable femtosecond pulses across a broad range of wavelengths. The technology is built on robust, patent-pending fiber-laser innovations, providing reliable and user-friendly operation through an embedded web server. Chromacity also collaborates with systems manufacturers to supply custom OEM femtosecond and picosecond lasers tailored to specific engineering and materials processing needs. Founded in 2013 as a spin-out from Heriot-Watt University, the company leverages over 40 years of expertise in ultrafast lasers and serves clients in North America, the United Kingdom, the Middle East, and beyond.

Adaptix Limited, established in 2009 and headquartered in Oxford, UK, specializes in designing and manufacturing innovative 3D radiology imaging equipment for X-ray applications. The company's core product is a miniaturized, flat panel X-ray source that can be integrated into existing product lines, enabling manufacturers to offer low-dose 3D imaging capabilities at a more affordable price point and with enhanced portability. Adaptix's solutions are used in various medical fields, including bedside chest imaging, extremity imaging, dental imaging, and breast imaging, with the potential to improve diagnostic accuracy for conditions like cardiovascular and pulmonary diseases, lung cancer, and osteoporosis. The company's technology, based on a pixelated array made in a semiconductor foundry, is protected by patents and leverages existing technologies from various industries. Adaptix's products are components intended for integration by X-ray systems manufacturers, who are responsible for product qualification, validation, and regulatory compliance.

Lamellar Biomedical Ltd. is a biotechnology company based in Bellshill, United Kingdom, focused on developing and commercializing medical devices and pharmaceuticals that leverage mimetics of extra-alveolar lamellar bodies. The company offers Lamellasomes, a synthetic product designed to replicate the functions of lamellar bodies, primarily targeting respiratory diseases such as cystic fibrosis, as well as conditions like dry eye disease and radiotherapy-induced xerostomia. Established in June 2007, Lamellar Biomedical acquired the intellectual property rights to this innovative technology, which aims to improve treatment outcomes through anti-infective properties that enhance antibiotic efficacy and facilitate the delivery of genetic material for pulmonary disease therapies. The company's efforts are directed towards providing transformative solutions for complex and rare respiratory conditions.

Chromacity Ltd. is a company based in Edinburgh, United Kingdom, that specializes in the development, manufacture, and distribution of wavelength tunable femtosecond lasers for various applications in life sciences and spectroscopy. The company's product lineup includes several advanced laser systems, such as the Spark 1030-nm and Spark-HP 1040-nm femtosecond lasers, which are designed for high performance and versatility. Additionally, Chromacity offers femtosecond optical parametric oscillators (OPOs), such as the Spark-OPO and Spark-ultra, which produce tunable femtosecond pulses across a broad range of wavelengths. The technology is built on robust, patent-pending fiber-laser innovations, providing reliable and user-friendly operation through an embedded web server. Chromacity also collaborates with systems manufacturers to supply custom OEM femtosecond and picosecond lasers tailored to specific engineering and materials processing needs. Founded in 2013 as a spin-out from Heriot-Watt University, the company leverages over 40 years of expertise in ultrafast lasers and serves clients in North America, the United Kingdom, the Middle East, and beyond.

MOFgen Ltd is a pioneering company that specializes in the commercialization of metal-organic frameworks (MOFs) for medical and therapeutic applications. Originating as a spin-out from the University of St Andrews, the company leverages patented technology developed by renowned porous material scientist Prof Russell Morris. MOFgen focuses on designing, manufacturing, and formulating MOFs to create innovative solutions for healthcare challenges. Its products include powdery solids with microscopic pores capable of incorporating antibacterial agents, wound healing compounds, and anti-thrombotic substances. These advanced coatings for medical devices aim to enhance patient care by reducing infection rates and minimizing the need for prolonged hospital stays. Through collaboration with various partners, MOFgen is committed to developing tailored solutions for issues such as healthcare-associated infections, bacterial resistance, chronic wounds, and arterial access.

Clear Surgical Ltd is a medical device company founded in 2013 and based in Larbert, United Kingdom. The company specializes in designing, manufacturing, and selling innovative devices for surgical use. Its notable products include The Oplight, an LED-based device that illuminates surgical cavities to enhance visibility during procedures, and Cannulated Reduction Forceps, which integrate a guidance system to facilitate optimal implant placement in orthopedic surgeries. Clear Surgical aims to improve surgical outcomes and efficiency in healthcare delivery through its advanced technologies.

Chromacity Ltd. is a company based in Edinburgh, United Kingdom, that specializes in the development, manufacture, and distribution of wavelength tunable femtosecond lasers for various applications in life sciences and spectroscopy. The company's product lineup includes several advanced laser systems, such as the Spark 1030-nm and Spark-HP 1040-nm femtosecond lasers, which are designed for high performance and versatility. Additionally, Chromacity offers femtosecond optical parametric oscillators (OPOs), such as the Spark-OPO and Spark-ultra, which produce tunable femtosecond pulses across a broad range of wavelengths. The technology is built on robust, patent-pending fiber-laser innovations, providing reliable and user-friendly operation through an embedded web server. Chromacity also collaborates with systems manufacturers to supply custom OEM femtosecond and picosecond lasers tailored to specific engineering and materials processing needs. Founded in 2013 as a spin-out from Heriot-Watt University, the company leverages over 40 years of expertise in ultrafast lasers and serves clients in North America, the United Kingdom, the Middle East, and beyond.

Taragenyx Ltd. is an orthopedic biotechnology company based in Glasgow, United Kingdom, specializing in the development of self-healing implant technologies aimed at enhancing the body's natural repair processes. Established in 2010, the company focuses on a range of applications within spine, trauma, extremities, and biologics. Taragenyx creates innovative therapeutic implants, incorporating bio-passive, bio-active, and bio-regenerative coatings that integrate active pharmaceuticals and biologics into the implant surface. This technology allows for localized release of compounds post-operatively, which can accelerate bone growth, promote faster healing, and reduce the risk of infection and pain. The company’s products are specifically designed to address limb-threatening surgical complications, thereby improving patient outcomes in orthopedic and dental procedures.

Clear Surgical Ltd is a medical device company founded in 2013 and based in Larbert, United Kingdom. The company specializes in designing, manufacturing, and selling innovative devices for surgical use. Its notable products include The Oplight, an LED-based device that illuminates surgical cavities to enhance visibility during procedures, and Cannulated Reduction Forceps, which integrate a guidance system to facilitate optimal implant placement in orthopedic surgeries. Clear Surgical aims to improve surgical outcomes and efficiency in healthcare delivery through its advanced technologies.

Sirakoss is a medical device company based in Scotland that specializes in the development of synthetic bone graft substitutes. The company focuses on creating innovative solutions for trauma, spine, craniomaxillofacial, and dental applications. Sirakoss is advancing its proprietary MaxSi™ Graft technology, which is available in granular and putty forms. This technology is designed to facilitate the fusion of bones, addressing various conditions including congenital and degenerative issues. By providing effective treatment options, Sirakoss aims to enhance patient recovery and support a return to healthy lifestyles.

UWI Technology Limited, founded in 2009 and based in Edinburgh, United Kingdom, specializes in innovative label solutions designed to enhance product safety and consumption. The company's flagship product, UWI Label, is an elapsed time indicator that informs users when a jar or container was first opened and tracks how long it has remained open. This technology is particularly useful in various sectors, including pharmaceuticals, medical devices, industrial applications, food and beverages, and cosmetics. By providing critical information about product usage and expiration, UWI Technology aims to mitigate the risks associated with using outdated or potentially harmful products, thereby promoting safety and efficiency in consumption.

Ocutec Ltd. is a company based in Bellshill, United Kingdom, that specializes in designing, developing, and marketing polyethylene glycol-based contact lens materials for vision correction and eye care. Founded in 2001, Ocutec leverages the materials science expertise of Professor Neil Graham and his team at the University of Strathclyde to create innovative solutions. The company focuses on developing both thermoset and thermoplastic contact lens materials that utilize polyethylene glycol (PEG) polymer chemistry. This technology facilitates step-growth polymerization, resulting in hydrated lens surfaces that mimic the extracellular matrix. As a result, Ocutec's lenses enhance tear film stability, promote ocular health, and provide improved comfort for users, allowing them the freedom to see without spectacles.

Clear Surgical Ltd is a medical device company founded in 2013 and based in Larbert, United Kingdom. The company specializes in designing, manufacturing, and selling innovative devices for surgical use. Its notable products include The Oplight, an LED-based device that illuminates surgical cavities to enhance visibility during procedures, and Cannulated Reduction Forceps, which integrate a guidance system to facilitate optimal implant placement in orthopedic surgeries. Clear Surgical aims to improve surgical outcomes and efficiency in healthcare delivery through its advanced technologies.

DYSIS Medical Ltd. is a medical device company based in Edinburgh, United Kingdom, specializing in imaging systems for the non-invasive, in-vivo detection of cancerous and pre-cancerous lesions. The company has developed the DYSIS Colposcope, a digital device that assesses the aceto-whitening reaction and presents the findings in an intuitive map format. In addition to the colposcope, DYSIS Medical offers a range of accessories, including both disposable and reusable specula, diathermy loops, and coagulation balls, as well as software for image data management and development of the DYSISmap. Founded in 2002 and rebranded in 2011, DYSIS Medical aims to improve early detection of cancers, potentially addressing significant healthcare challenges globally. The company maintains sales offices in Tampa, Florida; Edinburgh; and Athens, Greece.

Taragenyx Ltd. is an orthopedic biotechnology company based in Glasgow, United Kingdom, specializing in the development of self-healing implant technologies aimed at enhancing the body's natural repair processes. Established in 2010, the company focuses on a range of applications within spine, trauma, extremities, and biologics. Taragenyx creates innovative therapeutic implants, incorporating bio-passive, bio-active, and bio-regenerative coatings that integrate active pharmaceuticals and biologics into the implant surface. This technology allows for localized release of compounds post-operatively, which can accelerate bone growth, promote faster healing, and reduce the risk of infection and pain. The company’s products are specifically designed to address limb-threatening surgical complications, thereby improving patient outcomes in orthopedic and dental procedures.

Lamellar Biomedical Ltd. is a biotechnology company based in Bellshill, United Kingdom, focused on developing and commercializing medical devices and pharmaceuticals that leverage mimetics of extra-alveolar lamellar bodies. The company offers Lamellasomes, a synthetic product designed to replicate the functions of lamellar bodies, primarily targeting respiratory diseases such as cystic fibrosis, as well as conditions like dry eye disease and radiotherapy-induced xerostomia. Established in June 2007, Lamellar Biomedical acquired the intellectual property rights to this innovative technology, which aims to improve treatment outcomes through anti-infective properties that enhance antibiotic efficacy and facilitate the delivery of genetic material for pulmonary disease therapies. The company's efforts are directed towards providing transformative solutions for complex and rare respiratory conditions.

UWI Technology Limited, founded in 2009 and based in Edinburgh, United Kingdom, specializes in innovative label solutions designed to enhance product safety and consumption. The company's flagship product, UWI Label, is an elapsed time indicator that informs users when a jar or container was first opened and tracks how long it has remained open. This technology is particularly useful in various sectors, including pharmaceuticals, medical devices, industrial applications, food and beverages, and cosmetics. By providing critical information about product usage and expiration, UWI Technology aims to mitigate the risks associated with using outdated or potentially harmful products, thereby promoting safety and efficiency in consumption.

mLED Limited, based in Glasgow, United Kingdom, specializes in the development and manufacture of gallium nitride micropixellated light-emitting diode (LED) arrays. The company focuses on micro-LED technology, providing system integrators with the tools necessary to create prototype and production units for a variety of applications, including industrial, medical, and commercial sectors. mLED's technology enables the production of application-specific light patterns tailored to specific pixel layouts and addressing, as well as custom-specified wavelengths and both continuous pulsed and modulated light patterns.

mLED Limited, based in Glasgow, United Kingdom, specializes in the development and manufacture of gallium nitride micropixellated light-emitting diode (LED) arrays. The company focuses on micro-LED technology, providing system integrators with the tools necessary to create prototype and production units for a variety of applications, including industrial, medical, and commercial sectors. mLED's technology enables the production of application-specific light patterns tailored to specific pixel layouts and addressing, as well as custom-specified wavelengths and both continuous pulsed and modulated light patterns.

Ocutec Ltd. is a company based in Bellshill, United Kingdom, that specializes in designing, developing, and marketing polyethylene glycol-based contact lens materials for vision correction and eye care. Founded in 2001, Ocutec leverages the materials science expertise of Professor Neil Graham and his team at the University of Strathclyde to create innovative solutions. The company focuses on developing both thermoset and thermoplastic contact lens materials that utilize polyethylene glycol (PEG) polymer chemistry. This technology facilitates step-growth polymerization, resulting in hydrated lens surfaces that mimic the extracellular matrix. As a result, Ocutec's lenses enhance tear film stability, promote ocular health, and provide improved comfort for users, allowing them the freedom to see without spectacles.

Syntropharma Limited is a pharmaceutical company based in Melrose, United Kingdom, founded in 2005. The company specializes in the production and distribution of skin patches that deliver proven medicines for various diseases, particularly targeting neurological conditions such as Alzheimer's disease and depression. Syntropharma focuses on reformulating commercially successful generic compounds into transdermal applications, aiming to enhance their clinical profiles. With a vision to develop innovative first and second-to-market products, the company intends to establish strong intellectual property and subsequently out-license these products to pharmaceutical partners.

Tayside Flow Technologies is a medical devices company, engages in the research, development, and commercialization of vascular devices based on an understanding of blood flow dynamics. It develops Spiral Laminar Flow technology to help restore the body’s natural method of transporting blood in situations where own vessels need to be replaced by prosthetic vascular grafts to repair diseased veins and arteries.

Ocutec Ltd. is a company based in Bellshill, United Kingdom, that specializes in designing, developing, and marketing polyethylene glycol-based contact lens materials for vision correction and eye care. Founded in 2001, Ocutec leverages the materials science expertise of Professor Neil Graham and his team at the University of Strathclyde to create innovative solutions. The company focuses on developing both thermoset and thermoplastic contact lens materials that utilize polyethylene glycol (PEG) polymer chemistry. This technology facilitates step-growth polymerization, resulting in hydrated lens surfaces that mimic the extracellular matrix. As a result, Ocutec's lenses enhance tear film stability, promote ocular health, and provide improved comfort for users, allowing them the freedom to see without spectacles.

Ocutec Ltd. is a company based in Bellshill, United Kingdom, that specializes in designing, developing, and marketing polyethylene glycol-based contact lens materials for vision correction and eye care. Founded in 2001, Ocutec leverages the materials science expertise of Professor Neil Graham and his team at the University of Strathclyde to create innovative solutions. The company focuses on developing both thermoset and thermoplastic contact lens materials that utilize polyethylene glycol (PEG) polymer chemistry. This technology facilitates step-growth polymerization, resulting in hydrated lens surfaces that mimic the extracellular matrix. As a result, Ocutec's lenses enhance tear film stability, promote ocular health, and provide improved comfort for users, allowing them the freedom to see without spectacles.

Syntropharma Limited is a pharmaceutical company based in Melrose, United Kingdom, founded in 2005. The company specializes in the production and distribution of skin patches that deliver proven medicines for various diseases, particularly targeting neurological conditions such as Alzheimer's disease and depression. Syntropharma focuses on reformulating commercially successful generic compounds into transdermal applications, aiming to enhance their clinical profiles. With a vision to develop innovative first and second-to-market products, the company intends to establish strong intellectual property and subsequently out-license these products to pharmaceutical partners.

B1 Medical develops and manufactures medical devices for orthopedics. B1 Medical develops and markets products such as soft tissue monitoring, fracture fixation and small joint prothesis products.